Adverse event reporting in clinical trials in Parkinson's Disease: Time for change

Mov Disord. 2018 Nov;33(11):1685-1687. doi: 10.1002/mds.27497. Epub 2018 Nov 1.

Authors

C Warren Olanow^{1

2}, Christopher Kenney³, Stephen Bandak³, Karl D Kieburtz^{2

4}

Affiliations

¹ Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA.
² Clintrex LLC, Sarasota, Florida, USA.
³ Acorda Therapeutics, Ardsley, New York, USA.
⁴ Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA.

PMID: 30383315
DOI: 10.1002/mds.27497

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antiparkinson Agents / adverse effects*
Clinical Trials as Topic*
Dyskinesia, Drug-Induced / epidemiology
Dyskinesia, Drug-Induced / etiology*
Humans
Parkinson Disease / drug therapy*

Substances

Antiparkinson Agents

Grants and funding

Funding provided by Biotie Therapies, Inc, which is now wholly owned by Acorda Therapeutics/International